Grants and Contributions:
Title:
Development of a unique next generation end-to-end antibody discovery platform
Agreement Number:
981804
Agreement Value:
$150,050.00
Agreement Date:
Jul 1, 2021 - Aug 31, 2023
Description:
This project will support the development a one-of-a-kind antibody discovery platform, through the integration of a new single B cell technology using innovative memory, plasma and repertoire B cell workflows, with Next Generation Sequencing (NGS), machine learning and recombinant protein production.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Victoria, British Columbia, CA V8Z 7X8
Reference Number:
172-2021-2022-Q3-981804
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
894660174
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 212 days. The total amended value is -37,944 dollars.
Amendment Date
Feb 6, 2023
Recipient's Operating Name:
ImmunoPrecise Antibodies
Recipient's Legal Name:
ImmunoPrecise Antibodies (Canada) Ltd
Federal Riding Name:
Esquimalt--Saanich--Sooke
Federal Riding Number:
59026
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: